BIG TECHNOLOGIES PLC (BIG) — Investment research note

Executive summary

Big Technologies, trading as Buddi, is a UK-listed vertical-SaaS / IoT business selling electronic-monitoring tags (GPS, RF, transdermal alcohol) and the Eagle monitoring platform to criminal-justice agencies on long-term, recurring-revenue contracts. Statutory revenue has gone sideways since FY23 (£55.2m → £50.3m FY24 → ~£49.7m FY25) on the loss of the Colombian contract and FX headwinds, but constant-currency ARR is growing 12% (£52.4m at YE25) and adjusted EBITDA margins remain >49% — meanwhile the business is consumed by litigation with its founder/former CEO Sara Murray, which has produced a £35m provision and an actual £31.5m initial settlement payment. The single most important point for valuation today is that the Buddi-Litigation cash outflow is now partly crystallised, removing one tail risk; what remains is whether the new management team can re-accelerate growth and what the SM Proceedings recover.

Fair value estimate

• Methodology: blended EV/EBITDA on sustainable adj. EBITDA plus an EV/ARR sanity check, with net cash bridged separately (post-settlement).
• Key assumptions: sustainable adj. EBITDA £24–28m; multiple 8x (bear) – 12x (bull); post-settlement net cash ~£62m (Jan-26 figure cited in FY25 trading update); 298.5m shares.
• Bear EV £192m + £62m cash = £254m → ~85p.
• Base EV £260m + £62m = £322m → ~108p.
• Bull EV £335m + £62m = £397m → ~133p.
• Fair value range: 85p – 120p; implied market cap £254m – £358m; mid ~£305m / ~102p.
• vs latest market cap £299.7m: roughly fair; central-case upside ~2%, with ~−15% downside / +20% upside in the corners.

Sector context

• ICB Technology / Software & Services is correct, but functionally this is vertical govtech / criminal-justice IoT — closer to GeoGroup (NYSE:GEO) and Serco (LSE:SRP) than to broad UK tech. Other reference points: G4S (private), Attenti (Aetos, private).
• Quality vs sector peers: gross margin (67–70%) and adj. EBITDA margin (~50%) are above sector-typical, balance sheet is materially stronger than peers (net cash vs net debt at GEO/Serco), but growth, governance, and customer concentration are below typical quality vertical-SaaS comps.

Investment thesis

1. Recurring, contracted revenue base growing 12% on constant currency: ARR £52.4m at YE25, NRR 102%, and a roster of new wins (Northern Ireland MoJ, Queensland, Lithuania, Latvia, Pierce County, PEI, Aruba, Switzerland) that commence operation in 2026 2026-01 FY trading update; 2025-12 trading update.
2. Fortress balance sheet even after litigation cash-out: £93.4m cash YE25, £61.9m pro-forma after the £31.5m initial Buddi-Litigation payment; no debt; >£20m annual adj. operating cash generation — gives the new team time to re-accelerate growth without dilution risk 2026-01 FY trading update; 2025-09 interim results.
3. Operating leverage on a SaaS-like cost base: gross margin 67.5% with ~50% adj. EBITDA margin; new product launches (AlcoTag, AlcoBreath) extend the addressable wallet per offender without proportional cost; an in-housed US monitoring centre in Tampa adds fixed capacity to absorb US contract wins 2025-09 interim; 2025-12 trading update.

Key risks

1. Buddi Litigation tail: provision is set at the £35m mid-point of a £15–55m range; claimants have indicated they will pursue a higher quantification; the £31.5m initial payment is partial, not final 2025-09 interim, Notes 9/14/16.
2. Customer concentration and FX: two customers >10% each accounted for 44% of FY24 revenue; cost base in GBP vs revenue in AUD/NZD/USD — H1 2025 guidance cut by c.10% on EBITDA from FX alone 2025-05 audited FY24 results; 2025-09 interim.
3. Governance / founder overhang: AGM 2025 saw resolutions defeated by the founder's vote block; voting rights on 17.2% have been suspended by the company under DTR 5 — a contested register and the SM Proceedings (recovery of ">£19m" of diverted funds) remain unresolved and could trigger further disclosure or M&A delays 2025-06 AGM result; 2025-06 suspension of voting rights.

Operating leverage

The fixed-cost share is meaningful but not pure-software. Gross margin sits at 67.5% (H1 2025) / 68.1% (FY24); adj. EBITDA margin ran at 53.7% FY24 falling to ~49% FY25 on FX and pricing — implying a contribution margin on incremental revenue still in the 60–70% range given underlying cost discipline (administrative expenses ex-FX held flat from H1 24 to H1 25 at £7.3–7.5m 2025-09 interim). The hardware is in-house manufactured and leased, so working-capital and depreciation scale with new contract wins, but central R&D (£1.9m H1) and PLC overhead are fixed. A 10–20% revenue beat on the current ~£50m base would plausibly add ~50–80% to adjusted operating profit (from c.£19–20m towards £30m+), particularly as the AlcoTag/AlcoBreath ramp-up rides on the same monitoring infrastructure. The new Tampa monitoring centre is a fresh fixed-cost site that would scale efficiently if US new business wins compound.

Value-trap signals

• Two consecutive years of declining headline revenue (FY24 −9%, FY25 −1%).
• Material ongoing litigation absorbing management time and £42.6m of H1 25 P&L charges (provisions + legal costs).
• Related-party transactions with the former CEO's companies (TFM Developments, £50–100k p.a. license fees on disputed IP).
• Prior-period restatement of deferred tax (FY23) — accounting/disclosure quality has been tested.
• Reduced future dilution from buyback of Sara Murray's A-shares is a positive offset, but voting-rights suspension on 17.2% is itself a fragile governance state.

Earnings vs expectations

Against the (small) sell-side panel of five analysts:

• FY24 delivered revenue £50.3m vs guided consensus £50.1m and adj. EBITDA £27.0m vs consensus £26.7m — slight beat / in line 2025-01 trading statement; 2025-05 audited results.
• H1 2025: management pre-announced ~£24.8m / £12.5m EBITDA in July 2025, matched in the September interims — met guidance, but consensus had been cut earlier in the period for FX.
• FY25 trading update: revenue ~£49.7m vs consensus £49.1m and adj. EBITDA ~£24.6m vs consensus £24.1m — marginally ahead 2026-01 FY trading update. Pattern: post the Colombia disappointment in early 2024, management has rebased expectations and met or marginally beaten them; the track record is one of guidance discipline rather than upside surprise.

Conviction

Conviction: 3 (moderate). Anchored by: (a) very clear ARR disclosure and a SaaS-style economic profile that lends itself to multiple-based valuation; (b) a clean net-cash balance sheet making the equity-vs-EV bridge unambiguous; (c) a consistent recent track record of meeting rebased guidance. Limited by: (i) the still-uncertain Buddi-Litigation final settlement (the £35m provision sits inside a £15–55m claimant range, and the company itself says outcomes "may substantially differ"); (ii) early-stage tenure of the new CEO/CFO — sustainable margin and contribution-margin trajectory under the new pricing posture (deliberately more competitive) is not yet observable.

Driver scoring summary

• AI beneficiary: low. Eagle includes "AI features" (summarisation, location analytics) but BIG is a spender on AI as a product feature, not a recipient of AI capex; addressable market does not expand materially as agentic AI is adopted.
• Operating leverage: moderate-to-high. SaaS-like recurring revenue, 67% gross margin, fixed central cost base.
• Valuation discipline: stock is roughly fair on conservative central case; not "priced for perfection," not deeply cheap either.
• Downside protection: solid (net cash, debt-free, contracted revenue base, no going-concern issues even on severe downside in FY24 accounts).

Overall fit for this investor

Partial fit. Acceptable downside protection and a fair price, with some operating leverage — but the AI-receiver angle is weak (this is a govtech SaaS that uses AI internally, not a picks-and-shovels AI play), and the governance/litigation overhang caps the quality score.